Closely-held Ripple Therapeutics inked a transformative strategic investment and licensing deal for its lead product candidate, IBE-814 IVT, an intravitreal implant being developed for the treatment of diabetic macular...

Closely-held Genelux expects to arrange an end-of-Phase 2 meeting with the FDA in the first quarter of 2021 and then launch a Phase 3 trial in mid-year with its Olvi-Vec vaccinia virus in combination with chemotherapy...

Closely-held Micron Biomedical is developing a dissolvable microneedle-based technology that could enable self-administration of vaccines and therapeutics.

Closely-held Novamind is building the infrastructure required to facilitate safe, legal and medically-supervised psychedelic-assisted therapy. “We saw an opportunity to build a sustainable business in a market that’s...

Closely-held PregnanTech is completing a clinical safety study with its Lioness device to prevent preterm birth in non-pregnant women about to undergo a hysterectomy as a steppingstone to a larger proof-of-concept study...

Closely-held clinical metagenomics company, IDbyDNA, is commercializing its Explify platform with the goal of replacing traditional pathogen detection with a data-driven approach. “Our vision is to deploy our...

Closely-held Axolotl Biosciences is developing a bioink specifically formulated for the bioprinting of neural tissue, for biotechnology and pharmaceutical companies to use for research and development purposes. “Last...